Kemin’s FloraGLO Legacy Continues with New Blue Light Protection Patent

636040850652417747eyehealth.jpg

14 Jul 2016 --- The United States Patent and Trademark Office has issued Kemin Industries a patent for the role of its products in protecting individuals with three common ocular disorders from blue light or light-induced damage.

The royalty-free license for these products (FloraGLO Lutein and ZeaONE Zeaxanthin, distributed by DSM as OPTISHARP Natural) will provide a ‘huge market opportunity.’
 
Kemin’s patent (US Patent No. 9,226,940 B2) allows vitamin and dietary supplement manufacturers using FloraGLO and/or ZeaONE to position their products for blue light protection. The patent specifically covers products containing ocular antioxidants including lutein and zeaxanthin employed to protect the eye from light-induced damage, particularly the damage caused by the blue wavelengths of light.
 
The patent targets individuals with presbyopia, hyperopia or astigmatism. In these three conditions, blue wavelengths of light are focused directly onto the macula, creating a higher risk for ocular damage.
 
Blue light impacts the majority of adults ages 45 and older who have presbyopia, commonly known as age-related farsightedness.
 
“Because of the widespread prevalence of presbyopia, this patent opens the door for FloraGLO and OPTISHARP Natural customers to make blue light eye protection claims when targeting consumers 45 years and older,” said Dr. Richard Roberts, Patent Inventor and Principal Manager of Scientific Affairs and Technical Services for the Human Nutrition and Health division of Kemin.
 
Nearly every source of light—whether natural or artificial—emits harmful blue wavelengths of light.
The growing prevalence of digital devices like computers, tablets and smartphones is exposing individuals to more blue light than ever before.
 
Over half of Americans use digital devices more than five hours a day and 70% use two or more devices at the same time.
 
In addition to blue light from digital devices, the use of the light emitting diode (LED) in indoor lighting is another growing source of blue light exposure. LED bulbs contain 35% blue light levels as compared to 3% levels in traditional incandescent bulbs. In North America alone, LED lighting made up a US$4.8 billion market in 2012 and is expected to make up a US$42 billion market by 2019.
 
As blue light levels and sources continue to grow, children are especially vulnerable to the effects. Blue light exposure is especially concerning for infants and young children, as nearly every child is born with hyperopia, commonly known as farsightedness. Because of the condition, they are at a higher risk for blue light and light-induced damage as their eyes develop.
 
“Children are exposed to blue light more than ever before. Believe it or not, greater than half of American children use digital devices two or more hours a day,” said Heather Richardson, Vision Platform Senior Product Manager for the Human Nutrition and Health division of Kemin. “Our patent can help customers address this growing concern and develop blue light protection products for kids.”
 
“We are pleased to be able to offer a royalty-free license of our patent to customers who are interested in marketing blue light protection products to adults 45+ and children ages 0-2,” said Anita Norian, President of the Human Nutrition and Health division of Kemin. “It is clear this will be a huge market opportunity for our customers as the concern of blue light exposure and consumer awareness grows.”

Related Articles

Nutrition & Health News

Research driving demand for OPO in China’s formula market: Advanced Lipids

16 Feb 2018 --- OPO is increasing in popularity in China’s infant formula market, and according to Advanced Lipids, this is down to the growing body of scientific research backing the benefits of this ingredient. Also known as SN-2 palmitate, OPO is a premium quality ingredient that mimics the fatty acid profile of human milk.

Business News

Natures Crops, De Wit Speciality Oils enter into European distribution partnership for Ahiflower oil

15 Feb 2018 --- Natures Crops International and De Wit Speciality Oils have entered into a distribution agreement for Ahiflower oil in the European dietary supplement marketplace. This alliance is thought to add strategic value for both companies through each company’s leading position in manufacturing and marketing nutraceutical products.

Nutrition & Health News

Clear definition and regulations needed to tap into nutraceuticals’ potential: review

13 Feb 2018 --- Nutraceuticals with health benefits substantiated by clinical data can be powerful tools to prevent and treat medical conditions, especially in individuals who may not yet be eligible for conventional pharmaceutical drugs. However, there is a clear need for clear regulations to ensure their safety. This is according to a review published in the British Journal of Clinical Pharmacology, which further proposes a clear definition for this type of product. 

Business News

AI and personalized nutrition: Nestlé and Nuritas partner on bioactive peptide development

09 Feb 2018 --- Nestlé and biotech company Nuritas have entered into a collaboration aiming to uncover bioactive peptide networks within “specific target areas of significant value.” The precise areas of investigation are not yet being shared, with Nuritas Commercial Manager Neil Foster telling NutritionInsight that these details and the expected launch date are “at this early stage understandably confidential.” As part of the collaboration, Nuritas is to deploy its novel technology platform, which uses Artificial Intelligence and DNA analysis to predict, unlock and validate highly efficacious peptides, exclusively from natural food sources. Nestlé will use their considerable scientific know-how and applications expertise to validate the efficacy of these discoveries within the target applications.

Nutrition & Health News

What happens in the gut after too much fructose? Mouse study sheds light on role of small intestine

07 Feb 2018 --- In mice, fructose is processed mainly in the small intestine, not in the liver as had previously been suspected, Princeton University researchers report. However, sugary drinks and processed high-sugar foods may overwhelm the small intestine and spill into the liver for processing. Additionally, the authors note that the ability of the small intestine to process fructose is higher after a meal. Although the study was conducted in mice, the researchers recommend "the most old-fashioned advice in the world" for humans: Limit sweets to moderate quantities after meals, and do not have sweet drinks away from meal time.

More Articles
URL : http://www.nutritioninsight.com:80/news/kemins-floraglo-legacy-continues-with-new-blue-light-protection-patent.html